Cargando…

Utility of Serum Growth Arrest-Specific Protein 6 as a Biomarker of Severity and Prognosis After Severe Traumatic Brain Injury: A Prospective Observational Study

OBJECTIVE: Growth arrest-specific protein 6 (Gas6) may harbor protective effects in acute brain injury. This study was designed to determine the relation of serum Gas6 levels to severity and prognosis after traumatic brain injury (TBI). METHODS: In this prospective cohort study of 114 controls and 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Bu-Kao, Cai, Jian-Yong, Wang, Xiao-Bo, Lin, Qun, Zhang, Xue-Na, Wu, Jian-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293383/
https://www.ncbi.nlm.nih.gov/pubmed/35859802
http://dx.doi.org/10.2147/NDT.S372904
_version_ 1784749618049843200
author Ni, Bu-Kao
Cai, Jian-Yong
Wang, Xiao-Bo
Lin, Qun
Zhang, Xue-Na
Wu, Jian-Hua
author_facet Ni, Bu-Kao
Cai, Jian-Yong
Wang, Xiao-Bo
Lin, Qun
Zhang, Xue-Na
Wu, Jian-Hua
author_sort Ni, Bu-Kao
collection PubMed
description OBJECTIVE: Growth arrest-specific protein 6 (Gas6) may harbor protective effects in acute brain injury. This study was designed to determine the relation of serum Gas6 levels to severity and prognosis after traumatic brain injury (TBI). METHODS: In this prospective cohort study of 114 controls and 114 patients with severe TBI, multivariate analysis was used to assess relationships between serum Gas6 levels, Glasgow coma scale (GCS) score, Rotterdam computed tomography (CT) score, postinjury 180-day mortality, overall survival and poor prognosis (Extended Glasgow outcome scale score 1–4). RESULTS: Significantly increased serum Gas6 levels of patients (median, 10.3 ng/mL versus 32.5 ng/mL; P < 0.001), as compared with controls, were independently correlated with Rotterdam CT score (t = 3.629, P < 0.001) and GCS score (t=−3.393, P = 0.001), and independently predicted 180-day mortality (odds ratio, 1.078; 95% confidence interval (CI), 1.007–1.154), overall survival (hazard ratio, 1.074; 95% CI, 1.012–1.139) and poor prognosis (odds ratio, 1.129; 95% CI, 1.059–1.205). Areas under receiver operating characteristic curve (AUCs) of serum Gas6 levels for discriminating risks of 180-day mortality and poor prognosis were 0.785 (95% CI, 0.699–0.857) and 0.793 (95% CI, 0.707–0.863), respectively; and serum Gas6 levels above 30.9 ng/mL and 28.3 ng/mL predicted 180-day mortality and poor prognosis with maximum Youden indices of 0.451 and 0.468, respectively. The predictive ability of serum Gas6 levels for mortality was similar to those of GCS score (AUC, 0.833; 95% CI, 0.751–0.896; P = 0.286) and Rotterdam CT score (AUC, 0.823; 95% CI, 0.740–0.888; P = 0.432). The discriminatory capability of serum Gas6 levels for the risk of poor prognosis was in the range of GCS score (AUC, 0.846; 95% CI, 0.766–0.906; P = 0.178) and Rotterdam CT score (AUC, 0.831; 95% CI, 0.750–0.895; P = 0.368). CONCLUSION: Serum Gas6 may appear as a promising biochemical parameter for aiding in the assessment of trauma severity and prediction of prognosis among patients with severe TBI.
format Online
Article
Text
id pubmed-9293383
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-92933832022-07-19 Utility of Serum Growth Arrest-Specific Protein 6 as a Biomarker of Severity and Prognosis After Severe Traumatic Brain Injury: A Prospective Observational Study Ni, Bu-Kao Cai, Jian-Yong Wang, Xiao-Bo Lin, Qun Zhang, Xue-Na Wu, Jian-Hua Neuropsychiatr Dis Treat Original Research OBJECTIVE: Growth arrest-specific protein 6 (Gas6) may harbor protective effects in acute brain injury. This study was designed to determine the relation of serum Gas6 levels to severity and prognosis after traumatic brain injury (TBI). METHODS: In this prospective cohort study of 114 controls and 114 patients with severe TBI, multivariate analysis was used to assess relationships between serum Gas6 levels, Glasgow coma scale (GCS) score, Rotterdam computed tomography (CT) score, postinjury 180-day mortality, overall survival and poor prognosis (Extended Glasgow outcome scale score 1–4). RESULTS: Significantly increased serum Gas6 levels of patients (median, 10.3 ng/mL versus 32.5 ng/mL; P < 0.001), as compared with controls, were independently correlated with Rotterdam CT score (t = 3.629, P < 0.001) and GCS score (t=−3.393, P = 0.001), and independently predicted 180-day mortality (odds ratio, 1.078; 95% confidence interval (CI), 1.007–1.154), overall survival (hazard ratio, 1.074; 95% CI, 1.012–1.139) and poor prognosis (odds ratio, 1.129; 95% CI, 1.059–1.205). Areas under receiver operating characteristic curve (AUCs) of serum Gas6 levels for discriminating risks of 180-day mortality and poor prognosis were 0.785 (95% CI, 0.699–0.857) and 0.793 (95% CI, 0.707–0.863), respectively; and serum Gas6 levels above 30.9 ng/mL and 28.3 ng/mL predicted 180-day mortality and poor prognosis with maximum Youden indices of 0.451 and 0.468, respectively. The predictive ability of serum Gas6 levels for mortality was similar to those of GCS score (AUC, 0.833; 95% CI, 0.751–0.896; P = 0.286) and Rotterdam CT score (AUC, 0.823; 95% CI, 0.740–0.888; P = 0.432). The discriminatory capability of serum Gas6 levels for the risk of poor prognosis was in the range of GCS score (AUC, 0.846; 95% CI, 0.766–0.906; P = 0.178) and Rotterdam CT score (AUC, 0.831; 95% CI, 0.750–0.895; P = 0.368). CONCLUSION: Serum Gas6 may appear as a promising biochemical parameter for aiding in the assessment of trauma severity and prediction of prognosis among patients with severe TBI. Dove 2022-07-14 /pmc/articles/PMC9293383/ /pubmed/35859802 http://dx.doi.org/10.2147/NDT.S372904 Text en © 2022 Ni et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Ni, Bu-Kao
Cai, Jian-Yong
Wang, Xiao-Bo
Lin, Qun
Zhang, Xue-Na
Wu, Jian-Hua
Utility of Serum Growth Arrest-Specific Protein 6 as a Biomarker of Severity and Prognosis After Severe Traumatic Brain Injury: A Prospective Observational Study
title Utility of Serum Growth Arrest-Specific Protein 6 as a Biomarker of Severity and Prognosis After Severe Traumatic Brain Injury: A Prospective Observational Study
title_full Utility of Serum Growth Arrest-Specific Protein 6 as a Biomarker of Severity and Prognosis After Severe Traumatic Brain Injury: A Prospective Observational Study
title_fullStr Utility of Serum Growth Arrest-Specific Protein 6 as a Biomarker of Severity and Prognosis After Severe Traumatic Brain Injury: A Prospective Observational Study
title_full_unstemmed Utility of Serum Growth Arrest-Specific Protein 6 as a Biomarker of Severity and Prognosis After Severe Traumatic Brain Injury: A Prospective Observational Study
title_short Utility of Serum Growth Arrest-Specific Protein 6 as a Biomarker of Severity and Prognosis After Severe Traumatic Brain Injury: A Prospective Observational Study
title_sort utility of serum growth arrest-specific protein 6 as a biomarker of severity and prognosis after severe traumatic brain injury: a prospective observational study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293383/
https://www.ncbi.nlm.nih.gov/pubmed/35859802
http://dx.doi.org/10.2147/NDT.S372904
work_keys_str_mv AT nibukao utilityofserumgrowtharrestspecificprotein6asabiomarkerofseverityandprognosisafterseveretraumaticbraininjuryaprospectiveobservationalstudy
AT caijianyong utilityofserumgrowtharrestspecificprotein6asabiomarkerofseverityandprognosisafterseveretraumaticbraininjuryaprospectiveobservationalstudy
AT wangxiaobo utilityofserumgrowtharrestspecificprotein6asabiomarkerofseverityandprognosisafterseveretraumaticbraininjuryaprospectiveobservationalstudy
AT linqun utilityofserumgrowtharrestspecificprotein6asabiomarkerofseverityandprognosisafterseveretraumaticbraininjuryaprospectiveobservationalstudy
AT zhangxuena utilityofserumgrowtharrestspecificprotein6asabiomarkerofseverityandprognosisafterseveretraumaticbraininjuryaprospectiveobservationalstudy
AT wujianhua utilityofserumgrowtharrestspecificprotein6asabiomarkerofseverityandprognosisafterseveretraumaticbraininjuryaprospectiveobservationalstudy